================================================================================
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported) March 7, 2007
MEDIFAST, INC.
(Exact name of registrant as specified in its charter)
Delaware 000-23016 13-3714405
--------------------------------- ------------ -------------
(State or other jurisdiction (Commission (IRS Employer
of incorporation or organization) File Number) Ident. No.)
11445 Cronhill Drive, Owing Mills, Maryland 21117
------------------------------------------- ----------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (410)-581-8042
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
================================================================================
ITEM 7.01 REGULATION FD DISCLOSURE
The following information is furnished under "Item 7.01. Regulation FD
Disclosure" and "Item 2.02. Disclosure of Results of Operations and Financial
Condition."
On March 7, 2007, Medifast, Inc. ("Medifast") issued a press release
setting forth Medifast's full-year 2007 revenue and diluted earnings per share
guidance. A copy of Medifast's press release is attached hereto as Exhibit 99.1
and hereby incorporated by reference.
ITEM 9.01 EXHIBITS
Exhibits pursuant to Item 7.01
99.1 Press release dated March 7, 2007, announcing 2007 revenue and
diluted earnings per share guidance
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
MEDIFAST, INC.
Dated: March 7, 2007
/s/ Michael S. McDevitt
---------------------------
Michael S. McDevitt
Chief Executive Officer
3